News | October 17, 2007

XTent to Present CUSTOM I, II Trial Data at TCT 2007

October 18, 2007 – XTENT Inc. announced that two-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company’s investigational Custom NX drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21
Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., director of Cardiology, University Medical Center, Utrecht, Netherlands, will present an historical overview and current perspective on the treatment of multivessel coronary disease and the treatment of long lesions. An overview of the Custom NX DES System with respect to the treatment of multivessel and diffuse disease will be discussed, along with the one-year follow-up results of the CUSTOM II Trial.

Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington Convention Center
Event: Evening Symposium – Delivering Safety to Today’s Patients

Professor Eberhard Grube, M.D., chief of Cardiology at the HELIOS Heart Center in Siebgurg, Germany and principal investigator of the CUSTOM I and II clinical trials, will review the results to date from Biolimus A9 DES clinical trials and registries. Professor Grube will present two-year results from the CUSTOM I clinical trial and one-year results from the CUSTOM II clinical trial.

Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, will provide an overview of the Custom NX technology in a presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the Percutaneous Treatment of Coronary Artery Disease (CAD)."

Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel, Grand Ballroom, 999 Ninth Street NW

Monday, October 22
Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

For more information: www.xtentinc.com


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now